How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than companies lacking these ingredients.

In the first six months of 2019, 47 IPOs raised nearly $6.3 billion -- the largest aggregate amount in the first half of any year since BioCentury began tracking financings in 1993. ...